Cargando…

Mucosal and transdermal vaccine delivery strategies against COVID-19

The years 2020 and 2021 have witnessed a COVID-19 pandemic caused by the SARS-CoV-2 virus. However, these years have also witnessed certain remarkable scientific achievements. Researchers across the globe have been trying extremely hard and accomplished in bringing vaccines a great variety of COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Ashwini, Kumar, Awanish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123923/
https://www.ncbi.nlm.nih.gov/pubmed/33993417
http://dx.doi.org/10.1007/s13346-021-01001-9
_version_ 1783693060170842112
author Kumar, Ashwini
Kumar, Awanish
author_facet Kumar, Ashwini
Kumar, Awanish
author_sort Kumar, Ashwini
collection PubMed
description The years 2020 and 2021 have witnessed a COVID-19 pandemic caused by the SARS-CoV-2 virus. However, these years have also witnessed certain remarkable scientific achievements. Researchers across the globe have been trying extremely hard and accomplished in bringing vaccines a great variety of COVID-19 vaccines. Though the route of administration for the majority of these vaccines has been the intramuscular route (invasive), some laboratories are developing formulations intended for transmucosal and transcutaneous (non-invasive) administration, which are in the early phases of pre-clinical and clinical development. This short report discusses these unconventional formulations against COVID-19, in brief, to stress the importance of research in the field of drug delivery. GRAPHICAL ABSTRACT: [Image: see text]
format Online
Article
Text
id pubmed-8123923
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-81239232021-05-17 Mucosal and transdermal vaccine delivery strategies against COVID-19 Kumar, Ashwini Kumar, Awanish Drug Deliv Transl Res Technical Report The years 2020 and 2021 have witnessed a COVID-19 pandemic caused by the SARS-CoV-2 virus. However, these years have also witnessed certain remarkable scientific achievements. Researchers across the globe have been trying extremely hard and accomplished in bringing vaccines a great variety of COVID-19 vaccines. Though the route of administration for the majority of these vaccines has been the intramuscular route (invasive), some laboratories are developing formulations intended for transmucosal and transcutaneous (non-invasive) administration, which are in the early phases of pre-clinical and clinical development. This short report discusses these unconventional formulations against COVID-19, in brief, to stress the importance of research in the field of drug delivery. GRAPHICAL ABSTRACT: [Image: see text] Springer US 2021-05-15 2022 /pmc/articles/PMC8123923/ /pubmed/33993417 http://dx.doi.org/10.1007/s13346-021-01001-9 Text en © Controlled Release Society 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Technical Report
Kumar, Ashwini
Kumar, Awanish
Mucosal and transdermal vaccine delivery strategies against COVID-19
title Mucosal and transdermal vaccine delivery strategies against COVID-19
title_full Mucosal and transdermal vaccine delivery strategies against COVID-19
title_fullStr Mucosal and transdermal vaccine delivery strategies against COVID-19
title_full_unstemmed Mucosal and transdermal vaccine delivery strategies against COVID-19
title_short Mucosal and transdermal vaccine delivery strategies against COVID-19
title_sort mucosal and transdermal vaccine delivery strategies against covid-19
topic Technical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8123923/
https://www.ncbi.nlm.nih.gov/pubmed/33993417
http://dx.doi.org/10.1007/s13346-021-01001-9
work_keys_str_mv AT kumarashwini mucosalandtransdermalvaccinedeliverystrategiesagainstcovid19
AT kumarawanish mucosalandtransdermalvaccinedeliverystrategiesagainstcovid19